SDGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SDGR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The pre-market price is only slightly higher, but the technicals are mixed-to-weak, there is no strong proprietary buy signal, analyst targets have been cut recently, insiders are selling, and the short-term price pattern suggests downside over the next week and month. I would not call this an urgent buy today.
Current pre-market price is 14.7, up 0.68%. Trend signals are not bullish enough for a long-term entry: MACD histogram is -0.0289 and still negatively expanding, RSI_6 is 53.7 which is neutral, and moving averages are converging rather than trending strongly upward. Key levels show resistance near the pivot at 15.082, then R1 at 16.064, while support sits at 14.101 and 13.494. The stock trend model also points to weakness, with a 60% chance of -0.39% next day, -4.54% next week, and -11.82% next month.
No news in the recent week, so there are no fresh event-driven catalysts. Options positioning is mildly bullish, and the stock is slightly up in pre-market. The AI Stock Pick and SwingMax signals are both absent, so there is no proprietary trigger-based catalyst either.
Recent analyst price target cuts are negative, insider selling has increased sharply by 609.71% over the last month, hedge funds are neutral with no notable accumulation trend, and there is no recent news flow to support a re-rating. The short-term model also projects downside pressure over the coming days and weeks.
No usable latest-quarter financial snapshot was provided because of a data error, so I cannot assess the newest quarter season or growth trends from this dataset.
Analyst sentiment has weakened recently. Morgan Stanley cut its target to $17 from $19 and kept Equal Weight on 2026-05-14. KeyBanc lowered its target to $20 from $25 but stayed Overweight on 2026-04-13, citing generally positive setup ahead of Q1 earnings but cautious macro conditions. UBS cut its target to $13 from $18 and kept Neutral on 2026-03-17. Overall, Wall Street is mixed but trending more cautious, with the pros seeing some software/healthcare utilization support and the cons focused on macro uncertainty, valuation pressure, and weakening target prices.
